UBS Group
RPRX

UBS Group’s Repros Therapeutics Inc. RPRX Stock Holding History

UBS Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-23,781
Closed -$16K – 8630
2017
Q4 		$16K Sell
23,781
-6,673
-22% -$3.37K ﹤0.01% 6749
2017
Q3 		$10K Buy
30,454
+30,354
+30,354% +$10.6K ﹤0.01% 6928
2017
Q2 		$0 Sell
100
-1,209
-92% -$878 ﹤0.01% 8484
2017
Q1 		$1K Buy
1,309
+1,159
+773% +$1.45K ﹤0.01% 7577
2016
Q4 		$0 Sell
150
-3,531
-96% -$6.14K ﹤0.01% 8544
2016
Q3 		$7K Buy
3,681
+3,597
+4,282% +$7.12K ﹤0.01% 7037
2016
Q2 		$0 Sell
84
-4,311
-98% -$8.27K ﹤0.01% 8457
2016
Q1 		$4K Buy
4,395
+1,163
+36% +$1.14K ﹤0.01% 7162
2015
Q4 		$4K Buy
3,232
+2,980
+1,183% +$9.56K ﹤0.01% 7854
2015
Q3 		$2K Hold
252
– – ﹤0.01% 8180
2015
Q2 		$2K Sell
252
-1,927
-88% -$15K ﹤0.01% 8291
2015
Q1 		$19K Sell
2,179
-3,360
-61% -$30.1K ﹤0.01% 7065
2014
Q4 		$55K Buy
+5,539
New +$47.2K ﹤0.01% 6392

UBS Group's RPRX Position: Q1 2018 in Review

UBS Group sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 23,781 shares — an estimated $16K sold.

UBS Group first reported a position in RPRX in Q4 2014 and held it in 13 quarters. The position peaked at $55K in Q4 2014. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

  • UBS Group reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 23,781 Repros Therapeutics Inc. shares in Q1 2018, an estimated $16K.
  • UBS Group first reported a position in Repros Therapeutics Inc. in Q4 2014 and held it in 13 quarters.
  • UBS Group's Repros Therapeutics Inc. position peaked at $55K in Q4 2014.
  • 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.